$3.83
2.41% day before yesterday
Nasdaq, Nov 28, 09:24 pm CET
ISIN
US74017N1054
Symbol
PGEN

Precigen Inc Stock price

$3.83
-0.23 5.67% 1M
+2.46 179.56% 6M
+2.71 241.96% YTD
+2.92 321.16% 1Y
+2.06 116.38% 3Y
-4.09 51.64% 5Y
-32.13 89.35% 10Y
-19.78 83.78% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
+0.09 2.41%
ISIN
US74017N1054
Symbol
PGEN
Industry

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.3b
Net debt
positive
Cash
$59.8m
Shares outstanding
297.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
312.2 | 98.9
EV/Sales
298.5 | 94.5
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
45.9%
Return on Equity
-189.2%
ROCE
-120.0%
ROIC
-249.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$4.3m | $13.7m
EBITDA
$-91.9m | $-118.3m
EBIT
$-94.5m | $-103.8m
Net Income
$-124.5m | $-120.8m
Free Cash Flow
$-69.8m
Growth (TTM | estimate)
Revenue
-1.1% | 248.7%
EBITDA
-3.7% | -31.2%
EBIT
0.6% | -9.6%
Net Income
8.0% | 4.3%
Free Cash Flow
10.5%
Margin (TTM | estimate)
Gross
-0.7%
EBITDA
-2,116.5% | -863.5%
EBIT
-2,176.3%
Net
-2,868.7% | -881.4%
Free Cash Flow
-1,607.7%
More
EPS
$-0.4
FCF per Share
$-0.2
Short interest
15.1%
Employees
143
Rev per Employee
$30.0k
Show more

Is Precigen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Precigen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Precigen Inc forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Precigen Inc forecast:

Buy
80%
Hold
20%

Financial data from Precigen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4.34 4.34
1% 1%
100%
- Direct Costs 4.37 4.37
12% 12%
101%
-0.03 -0.03
95% 95%
-1%
- Selling and Administrative Expenses 49 49
24% 24%
1,137%
- Research and Development Expense 45 45
17% 17%
1,039%
-92 -92
4% 4%
-2,117%
- Depreciation and Amortization 2.59 2.59
60% 60%
60%
EBIT (Operating Income) EBIT -94 -94
1% 1%
-2,176%
Net Profit -125 -125
8% 8%
-2,869%

In millions USD.

Don't miss a Thing! We will send you all news about Precigen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Precigen Inc Stock News

Positive
Seeking Alpha
4 days ago
Precigen (PGEN) remains a Buy after PAPZIMEOS' FDA approval and launch, with higher-than-expected pricing and broad label supporting robust revenue potential. A new Pharmakon credit facility extends PGEN's cash runway into at least 2027, with management targeting cash-flow breakeven by the end of 2026. PAPZIMEOS' net price is ~$400,000 per patient annually, and redosing/early-line adoption coul...
Neutral
Seeking Alpha
16 days ago
Precigen, Inc. ( PGEN ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Steven Harasym - VP & Head of Investor Relations Helen Sabzevari - President, CEO & Director Phil Tennant - Chief Commercial Officer Rutul Shah - Chief Operating Officer Harry Thomasian - Chief Financial Officer Conference Call Participants Jason Butler - Citizens JMP Securities, LLC, Research Divis...
Neutral
PRNewsWire
16 days ago
PAPZIMEOS (zopapogene imadenovec-drba) received full approval by the FDA in August PAPZIMEOS launched with a broad label in the US as the first and only FDA-approved treatment for adults with RRP PAPZIMEOS is now available and shipping to prescribers in the US for the treatment of adults with RRP To date, over 100 patients have been registered in the PAPZIMEOS Patient Hub The Company has made s...
More Precigen Inc News

Company Profile

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, MBP Titan, Trans Ova and All Other. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The MBP Titan segment comprises of Methane Bioconversion Platform, and associated technologies, personnel, and facilities The Trans Ova segment includes provides advanced reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Head office United States
CEO Helen Sabzevari
Employees 143
Founded 1998
Website precigen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today